Treatment With Neuraminidase Inhibitors for Critically Ill Patients With Influenza A (H1N1)pdm09
| Autor: | Samuel Yang, Michael C. Samuel, Janice K. Louie, Robert Schechter, Timothy M. Uyeki, Hugo Guevara, Cynthia Yen, Meileen Acosta |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Neuraminidase inhibitor medicine.drug_class business.industry Medical record medicine.disease medicine.disease_cause Intensive care unit Comorbidity law.invention Infectious Diseases law Internal medicine Intensive care medicine Influenza A virus Young adult Intensive care medicine business Survival analysis |
| Zdroj: | Clinical Infectious Diseases. 55:1198-1204 |
| ISSN: | 1537-6591 1058-4838 |
| DOI: | 10.1093/cid/cis636 |
| Popis: | Background Neuraminidase inhibitor (NAI) antiviral drugs can shorten the duration of uncomplicated influenza when administered early ( Methods We analyzed California surveillance data to characterize the outcomes of patients in intensive care units (ICUs) treated with NAIs for influenza A(H1N1)pdm09 (pH1N1). Demographic and clinical data were abstracted from medical records, using standardized case report forms. Results From 3 April 2009 through 10 August 2010, 1950 pH1N1 cases hospitalized in ICUs were reported. Of 1859 (95%) with information available, 1676 (90%) received NAI treatment, and 183 (10%) did not. The median age was 37 years (range, 1 week-93 years), 1473 (79%) had ≥1 comorbidity, and 492 (26%) died. The median time from symptom onset to starting NAI treatment was 4 days (range, 0-52 days). NAI treatment was associated with survival: 107 of 183 untreated case patients (58%) survived, compared with 1260 of 1676 treated case patients (75%; P ≤ .0001). There was a trend toward improved survival for those treated earliest (P Conclusions NAI treatment of critically ill pH1N1 patients improves survival. While earlier treatment conveyed the most benefit, patients who started treatment up to 5 days after symptom onset also were more likely to survive. Further research is needed about whether starting NAI treatment >5 days after symptom onset may also convey benefit. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|